Compare FCFS & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCFS | ABVX |
|---|---|---|
| Founded | 1988 | 2013 |
| Country | United States | France |
| Employees | N/A | 67 |
| Industry | Other Specialty Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 9.7B |
| IPO Year | 1996 | N/A |
| Metric | FCFS | ABVX |
|---|---|---|
| Price | $189.33 | $122.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $179.33 | $130.85 |
| AVG Volume (30 Days) | 242.3K | ★ 743.8K |
| Earning Date | 04-23-2026 | 03-23-2026 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | ★ 29.49 | N/A |
| EPS | ★ 7.42 | N/A |
| Revenue | ★ $3,661,043,000.00 | N/A |
| Revenue This Year | $16.17 | N/A |
| Revenue Next Year | N/A | $0.22 |
| P/E Ratio | $25.45 | ★ N/A |
| Revenue Growth | ★ 8.04 | N/A |
| 52 Week Low | $116.09 | $4.77 |
| 52 Week High | $199.60 | $148.83 |
| Indicator | FCFS | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 53.68 | 53.78 |
| Support Level | $178.78 | $106.37 |
| Resistance Level | $199.60 | $131.27 |
| Average True Range (ATR) | 6.12 | 5.01 |
| MACD | -1.08 | 1.08 |
| Stochastic Oscillator | 42.68 | 80.07 |
FirstCash Holdings Inc is an operator of pawn stores in the U.S., Latin America and the U.K. The company's primary line of business is the operation of retail pawn stores, also known as pawnshops. It also operates a retail POS payment solutions business. Its two business lines are organized into four reportable segments: The U.S. pawn segment consists of pawn operations in some of U.S. states and the District of Columbia; The Latin America pawn segment consists of pawn operations in Mexico, Guatemala, El Salvador and Colombia; The U.K. pawn segment consists of pawn operations in England, Scotland and Wales; and The retail POS payment solutions segment consists of the operations of American First Finance, LLC, which offers products in the U.S.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.